Despite Scientific Challenges, Biopharmaceutical Researchers Making Progress against Rare Disease
While any given rare disease affects fewer than 200,000 people in the U.S., rare diseases cumulatively affect 1 in 10 Americans and an estimated 350 million people worldwide.
How can a program originally designed to help the deserving clinics treating our nation’s most vulnerable patients be used instead to pad the bottom line of large hospitals often providing minimal charity care? This is a question policymakers may be asking after seeing new data from the Berkeley Research Group on an obscure program called 340B.
PhRMA member companies are committed to ensuring patients can access the medicines they need to stay healthy and live longer, more productive lives. As part of this pledge, today we relaunched the Partnership for Prescription Assistance (PPA) website to provide patients and caregivers with faster, easier access to information on public and private patient assistance programs.
Hypertension, or high blood pressure, is a chronic condition affecting an estimated 70 million people in the United States. Unfortunately, just 52 percent of these individuals have their high blood pressure under control. Many people don’t realize taking their medicines as prescribed can help keep this chronic condition in check – and save money – for both individuals and the health care system overall.
This piece first appeared on WashingtonExec on February 25, 2015.
On Saturday, March 28, the Leukemia & Lymphoma Society (LLS) will host its 2015 Leukemia Ball. This annual black-tie event starts at 6:30 p.m. and will be held at the Walter E. Washington Convention Center, in Washington, D.C.
Many patients are not aware of the harmful effects that non-adherence to needed medicines can have on their health, lifestyle and the economy. This week, we explored the ways in which medication adherence and staying up-to-date on important health-related information can help patients.
Understanding how intrinsic intellectual property (IP) is to the United States economy (innovative industries support more than a quarter of all jobs in the U.S.), the Office of the U.S.
According to the Centers for Disease Control and Prevention, one in three American adults has high cholesterol. For those struggling with high cholesterol, getting needed prescriptions and adhering to the prescribed treatment regimen is critical.
I am excited to be in India this week to discuss the scientific landscape of pharmaceutical research and development. Everywhere I go I see so much potential for India to become a leader in the discovery and development of innovative medicines. India has a large cadre of well-trained pharmaceutical scientists and has more U.S.
For 50 years, the PhRMA Foundation has supported young scientists in their efforts to pursue careers in research and education that will ultimately lead to improved care and treatment options for patients.
Managing diabetes treatments is a big task. Medicare Part D helps patients access needed medicines, keeps costs low and helps avoid costly hospitalizations and complications.
The internet provides us with a wealth of information right at our fingertips, but it’s important to be mindful of misinformation, especially as it pertains to your health. With myths and facts swirling about important health topics this week, we cut through the clutter to bring you the facts.
Last year, PhRMA was joined by patient groups to highlight an analysis that found a majority of plans in health insurance exchanges required relatively high cost sharing for all medicines in at least one class. The cost burden leaves many patients with no other option, forcing them to make tough choices or go without needed medicines, ultimately having a negative impact on their health.
Last week, Food and Drug Administration (FDA) Commissioner Margaret Hamburg announced that she will step down from her post at the end of next month. PhRMA and its member companies appreciate Commissioner Hamburg’s years of dedication to health care innovation that helps America’s patients.
By Jennifer Bryant
According to a new report from actuaries Gabriela Dieguez, Bruce Pyenson and Jennifer Carioto, at Milliman, major pharmacy benefits managers (PBMs) often overestimate future spending on specialty medicines, sometimes by nearly 10 percentage points.
